Revolution Medicines (RVMD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Revolution Medicines (RVMD)
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Key Insights
Critical company metrics and information
Share Price
$48.07Market Cap
$8.09 BillionTotal Outstanding Shares
168.22 Million SharesTotal Employees
490Dividend
No dividendIPO Date
February 13, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.revmed.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-541.89 Million |
Net Cash Flow, Continuing | $-156.64 Million |
Net Cash Flow From Financing Activities | $924.96 Million |
Net Cash Flow From Investing Activities | $-541.89 Million |
Net Cash Flow From Financing Activities, Continuing | $924.96 Million |
Net Cash Flow | $-156.64 Million |
Net Cash Flow From Operating Activities | $-539.71 Million |
Net Cash Flow From Operating Activities, Continuing | $-539.71 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $343000.00 |
Diluted Earnings Per Share | $3.66 |
Research and Development | $553.19 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Other Operating Expenses | $95.75 Million |
Revenues | $742000.00 |
Diluted Average Shares | $341.23 Million |
Operating Expenses | $653.94 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-567.06 Million |
Basic Earnings Per Share | $3.66 |
Income/Loss From Continuing Operations After Tax | $-567.06 Million |
Net Income/Loss Attributable To Parent | $-567.06 Million |
Income/Loss From Continuing Operations Before Tax | $-566.72 Million |
Basic Average Shares | $341.23 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $-567.06 Million |
Operating Income/Loss | $-653.20 Million |
Nonoperating Income/Loss | $86.48 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $1.58 Billion |
Noncurrent Liabilities | $85.83 Million |
Assets | $1.76 Billion |
Accounts Payable | $24.46 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $196.69 Million |
Fixed Assets | $24.81 Million |
Equity | $1.57 Billion |
Equity Attributable To Parent | $1.57 Billion |
Other Non-current Assets | $102.11 Million |
Noncurrent Assets | $183.86 Million |
Liabilities And Equity | $1.76 Billion |
Other Current Liabilities | $86.41 Million |
Intangible Assets | $56.94 Million |
Current Liabilities | $110.86 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.